Radiation Therapy in Early Stage Endometrial Cancer: Update and Perspectives Arno J. Mundt MD Professor and Chair Department of Radiation Oncology
|
|
- Earl Howard Wade
- 7 years ago
- Views:
Transcription
1 Radiation Therapy in Early Stage Endometrial Cancer: Update and Perspectives Arno J. Mundt MD Professor and Chair Department of Radiation Oncology University of California San Diego
2 Radiation Therapy in Uterine Cancer Long history 1 st report published in 1909 Heyman (1935) reported a 58.2% 5-yr survival in early stage pts with the Stockholm Method (radium packing) Demonstrated curative potential of RT Heyman and Colleagues Radiumhemmet (1930s)
3 Historical Perspective Soon became commonplace, particularly pre-op By the 1980s, preoperative RT use declined Today, RT is almost exclusively delivered post-operatively in pts with adverse pathologic features Pelvic RT and/or vaginal brachytherapy (VB) Enthusiasm has waned for other previously popular approaches, e.g. whole abdominal RT (WART) and intra-peritoneal 32 P
4 When discussing preoperative RT, one needs to resurrect the old FIGO staging system Stage I IA IB Stage II Stage III Stage IV FIGO 1971 Clinical Staging System Corpus only Uterine cavity 8 cm Uterine cavity > 8 cm Corpus and cervix Extra-uterine disease (pelvis only) Extra-pelvic disease Rectal or bladder involvement FIGO =International Federation of Gynecology and Obstetrics
5 Preoperative RT Arguments Offered For Cytoreduction prior to surgery Spread of viable cells at surgery Better treatment tolerance Irradiation of well-oxygenated tumors Arguments Offered Against Over-treatment of low risk patients Loss of pathologic prognostic information* *most compelling argument (but overcome by operating within 2-3 days)
6 Preoperative RT Excellent pelvic control and survival in clinical stage I patients Pelvic 5-yr Year Control Survival Salazar % 82% Chung % 88% Bedwinek % 71% Weigensberg % 70-80%* Baram 1985 NS 72.4% Delmore % 84-91% Grigsby % 84% NS=not stated *5-yr DFS
7 Preoperative RT Serious complications are rare, particularly when brachytherapy is used alone Grigsby (1991) Retrospective review of 685 clinical stage I patients treated with preoperative RT Significant Treatment n GI toxicity ICB S % ICB + pelvic RT S % ICB S pelvic RT % ICB=intracavitary brachytherapy, S=surgery
8 Preoperative RT Greatest benefit in stage I g3 tumors Sause et al. (1990) Retrospective comparison of preop ICB versus surgery alone Grade 3/deep MI pts postop pelvic RT 5-year DFS All patients Grade 3 ICB S 94% 76% S 91% 53% Some institutions still recommend preoperative RT in clinical stage I g3 pts
9 Preoperative RT Stronger rationale exists in clinical stage II pts, particularly those with gross cervical involvement Analogous to bulky stage IB cervix pts
10 Preoperative RT 5-yr survivals in clinical stage II pts range from 70-80% Year 5-yr Survival Bruckman % Surwitt % Kinsella % (83% 5-yr DFS) Grigsby % Best outcomes in low grade tumors and those with microscopic cervical involvement Limited data in clinical stage III tumors
11 Preoperative RT What is the preferred preoperative RT approach? To answer this question, Wiegensberg (1984) performed a randomized trial Clinical Stage I Patients Regimen 1 ICB Hysterectomy Regimen 2 Pelvic RT Hysterectomy
12 Preoperative RT Preoperative ICB pts had Lower rate of residual disease Fewer pelvic failures Improved disease-free survival Fewer complications Residual Pelvic Disease Failure 5-yr DFS ICB S 50.9% 3.6% 80% Pelvic RT S 70% 12.6% 70% p =.02
13 Preoperative RT Technique ICB, pelvic RT or both Preferred approach in stage I disease is ICB alone Pelvic RT added in patients found to have deep MI and/or grade 3 disease In stage II pts, preoperative pelvic RT and ICB used
14 Preoperative RT Technique Heyman-Simon Capsules Traditionally low-dose-rate (LDR) techniques Fletcher-Suit combined with Heyman-Simon capsules mg-hr (vaginal apex Gy) If combined with pelvic RT, 2500 mg-hr intrauterine Some prescribe to Point A (à la cervical cancer) No recommendations for HDR brachytherapy
15 Is there a Future for Preoperative RT? Very limited at best At most centers today, only in clinical stage II pts with gross cervical involvement
16 Is preoperative superior to postoperative RT? To answer this question, the Gynecologic Oncology Group (GOG) launched GOG 16 Clinical Stage 1 Grade 1-3 Regimen 1 Preoperative RT Regimen 2 Postoperative RT However, it closed due to poor accrual Interest now turned to tailored postoperative RT
17 Postoperative RT
18 FIGO 1988 Surgical Staging System Early Stage Disease Stage I IA IB IC Stage II IIA IIB Corpus only Limited to the endometrium 1/2 myometrial invasion >1/2 myometrial invasion Corpus and cervix Endocervical glands only Cervical stromal invasion
19 Postoperative RT Early Stage Disease Very Contentious Issue All Patients Receive Adjuvant RT Even low grade minimally invasive tumors Center A No Patients Receive Adjuvant RT Even high grade Deeply invasive tumors Center B
20 Postoperative RT Early Stage Disease Controversy Exists Even When Given Pelvic RT Alone Pelvic RT + VB VB Alone Center A Center B Center C
21 Postoperative RT Rationale Early stage pts with adverse pathologic features are at risk for extra-uterine disease Most commonly cited pathologic factors: Myometrial invasion (MI) Tumor grade Cervical involvement Importance demonstrated in GOG 33
22 Surgical-pathologic study of 621 stage I pts Grade MI GOG 33 + Lymph Nodes Pelvic Paraortic 1 3% 2% 2 9% 5% 3 18% p< % p<.0007 None 1% 1% Superficial 5% 3% Middle 6% 1% Deep 25% p< % p<.0001 Creasman WT et al. Cancer 1987;60:2035
23 More useful to combine grade and MI +Pelvic Nodes Invasion G1 G2 G3 None 0% 3% 0% Inner 3% 5% 9% Middle 0% 9% 4% Deep 11% 19% 34% +Paraortic Nodes Invasion G1 G2 G3 None 0% 3% 0% Inner 1% 4% 4% Middle 5% 0% 0% Deep 6% 14% 23% Creasman WT et al. Cancer 1987;60:2035
24 Cervical involvement and CSI are also correlated with positive nodes + Lymph Nodes Pelvic Paraortic Site Fundus 8% 4% Isthmus-Cervix 16% p=.01 14% p=.0001 Capillary Space Involvement Negative 7% 4% Positive 27% p= % p=.0001 Creasman WT et al. Cancer 1987;60:2035
25 Rationale also provided by the correlation between adverse pathologic factors and vaginal failure Price (1965) 41 clinical stage I pts undergoing surgery alone Vaginal Recurrence All patients 14% Grade 1 4.4% 2 5.7% % MI None 3.7% <1/2 4.7% >1/2 15.1% Unfortunately, grade and MI not combined in the analysis Price et al. Am J Obstet Gynecol 1965;91:1060
26 Other Factors Other factors cited as risk factors for pelvic and/or vaginal failure: Tumor Size Schink (1991) Lower Uterine Segment (LUS) Mayr (1995) LUS is a common indication for adjuvant RT even without other high risk factors Schink et al. Cancer 1991;78:63 Mayr et al. Radiology 1995;196:323
27 Postoperative RT in Clinical Stage I Endometrial Cancer: Corpus, Cervical and Lower Uterine Segment Involvement- Patterns of Failure Mayr N et al. Radiology 1995;196:323 But. Only 4 patients with +LUS were treated with surgery alone 2/4 (50%) recurred And deep MI defined as >2/3 invasion Many or all four may have been stage IC
28 41 pathologic stage I pts All +LUS but negative cervical involvement Pelvic/Vaginal Recurrence -RT +RT Low Risk 0/25 0/2 ( 1/2 MI, g1-2) High Risk 3/6 1/8 (> ½ MI, g3) LUS involvement does not appear to be an independent risk factor for recurrence Phelan et al. Gynecol Oncol 2001:83:513
29 What evidence supports the use of adjuvant RT in stage I-II disease?
30 Numerous studies focused on postoperative RT in pathologic stage I-II pts Important differences exist Patients vary Some include only low risk tumors, others focus on high risk ones Surgical approaches vary Some include full surgical staging (pelvic and pelvic lymph node assessment) others do not RT approaches vary Some treat pts with pelvic RT, others focus on VB alone or pelvic RT + VB
31 Postoperative RT Stage I-II Disease Despite such differences, pelvic/vaginal control rates >95% in most reports Survival rates are also excellent Stage I 82-98% Stage II 68-93%
32 Selected Pathologic Stage I-II Postoperative RT Studies Recurrence 5-yr Author Stage RT Vagina Pelvis SV Alektiar IBg1-2 VB - 4% 94% Alektiar IB-IIB VB 2% 4% 93% Anderson IB-IC VB 0.9% 1.9% 84% Boz IAg3-IC P 4% 88% Calvin IIA-B P+/-VB,VB 2% 4% 85.2% Carey IBg3-II P+/-VB 3.9% 81% Chadha IBg3-IC VB 0% 81% Feltmate II P+/-VB,VB 3.7% 3.7% 93% Greven IA-IIB P+/-VB,VB 3.7% 0.7% 86% Nori I-II VB+/-P 2% 96.6% Rush IB-IC P 0% 0% 92% Weiss IC P 0% 1.6% 86%* Burke T, Muggia F, Mundt AJ. Uterine Cancer. In: Devita, Hellman, Rosenberg (eds). Principles and Practice of Oncology (2005)
33 Retrospective studies suggest a benefit to RT in pts with adverse pathologic factors Pelvic Recurrence +RT -RT Carey (1995) Hi risk pts 3.9%* 14.3% (deep MI, g3, +cervix) Pitson (2002) Stage II 5.6% 22.2% *includes non-irradiated patients Carey et al. Gynecol Oncol 1995;57:138 Pitson et al. Int J Radiat Oncol Biol Phys 2002;53:862
34 Retrospective review of 927 stage I-II patients Vaginal Recurrence +RT -RT Low risk stage I 0% 3.2% (g1-2, <1/3 MI) Hi risk stage I 1.1% 11.7% (g3, >1/3 MI) Stage II 0% 12.8% Elliott et al. Int J Gyne Cancer 1994:4:84
35 608 stage IA-IIA patients 22% pts with high risk features received adjuvant RT Multivariate analysis: adjuvant RT associated with DFS and Survival controlling for age, grade, stage, and surgical staging p-value HR 95% CI DFS OS Macdonald et al. Gynecol Oncol 2006;103:661
36 Postoperative RT Pathologic Stage I-II Disease Four prospective randomized clinical trials (RCT) have been performed evaluating postoperative RT in early stage patients Norwegian Trial PORTEC GOG-99 ASTEC/NCIC
37 Norwegian Trial Aalders (1980) Clinical Stage I N=540 TAH-BSO without lymph node sampling No assessment of peritoneal cytology Vaginal Brachytherapy 60 Gy vaginal surface Regimen 1 Pelvic RT 40 Gy (midline block after 20 Gy) Regimen 2 No further therapy Aalders et al. Obstet Gynecol 1980;56:419
38 Norwegian Trial Pelvic RT decreased vaginal/pelvic failures in pts with high risk features (deep MI, grade 3) tumors Vaginal/Pelvic Recurrence -Pelvic RT +Pelvic RT Grade 1-2 tumors 1/2 MI 4.0% 2.3% >1/2 MI 9.8% 9.4% Grade 3 tumors 1/2 MI 5.6% 2.1% >1/2 MI 19.6% 4.5% Aalders et al. Obstet Gynecol 1980;56:419
39 Norwegian Trial No overall benefit in survival with pelvic RT 5-yr Survival Pelvic RT 89% No Pelvic RT 91% Only in pts with deeply invasive g3 tumors Deaths from Cancer Pelvic RT 18.2% No Pelvic RT 27.5% Low risk pts had a higher rate of distant metastases leading to more cancer deaths! Aalders et al. Obstet Gynecol 1980;56:419
40 . PORTEC Trial Post Operative Radiation Therapy in Endometrial Carcinoma Creutzberg (2000) Select Stage I grade 1 >1/2 MI grade 2 any MI grade 3 <1/2 MI N=715 TAH-BSO without lymph node sampling No assessment of peritoneal cytology Regimen 1 Pelvic RT 46 Gy/ 2 Gy fractions No vaginal brachytherapy Regimen 2 No further therapy
41 PORTEC Trial Irradiated pts had a superior pelvic control 5-yr Pelvic Recurrence Pelvic RT 4% No Pelvic RT 14% p <.001 No benefit in overall survival Even after controlling for age, grade and MI 5-yr Survival Pelvic RT 81% No Pelvic RT 85% Creutzberg et al. Lancet 2000;355:1404
42 Locoregional Recurrence 14% 4% Creutzberg et al. Lancet 2000;355:1404
43 GOG 99 Trial Stage IB-II (occult) N=392 TAH-BSO with selective bilateral pelvic and para-aortic lymphadenectomy Assessment of peritoneal cytology Regimen 1 Pelvic RT 50.4 Gy/ 1.8 Gy fractions No vaginal brachytherapy Regimen 2 No further therapy Keys et al. Gynecol Oncol 2004;92:744
44 GOG 99 Trial Irradiated pts had a superior pelvic control 2-year Locoregional Recurrence Pelvic RT 3% No Pelvic RT 12% p <.01 RT pts had a non-significant improved survival 4-year Survival Pelvic RT 92% No Pelvic RT 86% p =.55
45 Survival Surgery +RT Surgery Keys et al. Gynecol Oncol 2004;92:744
46 Post-hoc analysis High Intermediate Risk (HIR) patients Age 70 with 1 of the following risk factors (grade 2-3, LVI, outer 1/3 MI) Age 50 with 2 factors Any age with all 3 factors Only 1/3 of treated patients A non-significant survival favoring RT Insufficient statistical power 4-year Survival Pelvic RT 88% No Pelvic RT 74% p = NS
47 ASTEC/NCIC Stage IA-IIA Intermediate/High Risk IA-IBg3, IC-IIA N= 905 TAH-BSO Assessment of peritoneal cytology and nodes not required If done, +cyto and +node patients included (1/3 of enrollment) Regimen 1 Pelvic RT Gy/ Gy fractions VB optional (54%) Regimen 2 Observation VB optional (52%) ASTEC/NCIC Committee Lancet 2009;373-46
48 Results No benefit to pelvic RT in terms of overall and cause-specific survival Significant reduction in local relapse as 1 st failure site 6.1% vs 3.2% Increase in lifethreatening acute (<1% vs 3%) and late (0% vs 1%) sequelae
49 What do these trials teach us?
50 Lesson 1 Adjuvant RT is associated with a significant and profound improvement in loco-regional control in early stage endometrial cancer, particularly in women with high risk features
51 Lesson 2 Adjuvant Pelvic RT is associated with increased toxicity, primarily related to the GI tract
52 Severe GI toxicity highest in GOG 99 Suggesting an increased risk in surgically staged patients PORTEC GOG-99 Severe GI Sequelae 3% (5-year, actuarial) 8% (2-year, crude) In GOG-99, 2 RT pts died from intestinal injury and 6 developed grade 3-4 SBO (compared to 1 non-rt pt)
53 Intensity Modulated RT Intensity modulated RT (IMRT) may decrease the risk of severe sequelae Dosimetric studies demonstrate significant sparing of small bowel, bladder and rectum Preliminary outcome studies have noted low toxicity rates and excellent pelvic control
54 Clinical Outcome Studies Adjuvant IMRT in Endometrial Cancer Pelvic Chronic n FU DFS Control Toxicity Knab m 84% 100% No G2 Beriwal m 84% 100% 3.3% 3 yr G2 Knab et al. Int J RadiatOncolBiolPhys 2004;60:303 Beriwal et al. Int J RadiatOncolBiolPhys 2006;102:195
55 What do the randomized trials not teach us?
56 Un-Answered Question 1 Does adjuvant RT Increase survival in early stage endometrial cancer patients?
57 Is Survival Increased? None of the trials found a significant benefit in survival with RT However, none were well-suited to answering this question
58 Limitation #1 Follow-up times are limited Longer follow-up of patients who recur may be necessary to assess impact on survival
59 Limitation #2 Only two trials contained surgery alone (control) arms All women in the Norwegian Trial received adjuvant VB Half the patients in ASTEC/NCIC received VB
60 Limitation #3 GOG 99 included many low risk patients (58% IB, 82% g1-2) PORTEC excluded high risk pts (Stage IC g3-ii) GOG 99 included patients least likely to benefit and PORTEC excluded those most likely to benefit
61 Meta-analysis of adjuvant RT in stage I endometrial cancer 4 randomized trials (3 published, 1 unpublished) 1770 patients Significant improvement in locoregional control Kong et al. Ann Oncol 2007
62 No improvement in survival seen in overall group Borderline survival advantage favoring RT Patients with 2 high risk factors (Grade 3, > ½ MI) Kong et al. Ann Oncol 2007
63 Review of SEER data 4010 stage IC g3-4 and stage II (all grades) 2306 pts (Surgery external beam +/- VB) 1704 pts (Surgery alone) Significant benefits in OS and CSS In stage IC g3-4, stage II g2, stage g3-4 Lee et al. JAMA 2006;295:389
64 Is Survival Increased? Far from an academic question Lack of a perceived survival benefit led some to withhold adjuvant RT, even in women with multiple high risk features Despite multiple randomized trials demonstrating a profound locoregional control benefit
65 Immediate versus Delayed RT Salvage rates may not be as high as those commonly quoted >70% results are typically quoted Most studies do not support this, even in isolated vaginal recurrences Survivals typically range around 40-50% Poorer outcomes in non-vaginal pelvic recurrences
66 Salvage RT Series Locally Recurrent Endometrial Cancer Local 5-yr Author n Control Survival Kuten (1989) 51 35% 18% Jereczek (2000) 73 48% 25% Curran (1988) 47 48% 31% Jhingran (2003) 91 75% 43% Hoekstra (1993) 26 84% 44% Sears (1994) 45 54% 44% Hart (1998) 26 65% 53% Wylie (2000) 58 65% 53% Lin (2005) 50 74% 53% Creutzberg ( 03) 35 77% 65%
67 Overall Survival is Poor Particularly in high grade tumor recurrences Lin et al. Int J Radiat Oncol Biol Phys 2005;63:500
68 And the risk of toxicity should not be ignored 22 isolated vaginal recurrences 18 EBRT+HDR, 4 HDR alone Median follow-up 32 month 18% grade 3-4 GI toxicity 50% grade 3 vaginal sequelae Petignat et al. Gynecol Oncol 2006;101:445
69 Recommendation Adjuvant RT should not be withheld in stage I-II patients due to a lack of a perceived survival benefit A more judicious approach is to properly select patients with high risk features If withheld, follow closely to detect recurrences quickly, hopefully when small and isolated to the vagina
70 Un-Answered Question 2 What is the optimal adjuvant RT approach in early stage patients?
71 Optimal Approach Much is made of the fact that many of the pelvic recurrences in the GOG 99 surgery arm were in the vaginal vault Prompted some investigators to recommend VB as the sole adjuvant therapy in early stage surgically staged patients
72 Optimal Approach However, while most pelvic failures were in the vagina, 28% were non-central (sidewall) Concerning since GOG 99 patients were surgically staged Most likely will be higher in patients with incomplete surgical staging Sidewall recurrences, even when small, are rarely salvaged Necessary doses associated with considerable toxicity risk even when IMRT is used
73 With adequate surgical staging, outcomes are excellent with VB alone Recurrences n Vagina Pelvis Solhjem 100 0% 0% Horowitz 164 1% 0.6% Chadha 38 0% 0% Fanning 22 0% 0% Hong % 0% Solhjem et al. Int J Radiat Oncol Biol Phys 2005;62:1379 Horowitz et al. Obstet Gynecol 2002;99:235 Chadha et al. Gynec Oncol 1999;75:103 Fanning et al. Obstet Gynecol 1996:87:1041 Hong et al. Am J Clin Oncol 1997;29:254
74 VB versus Pelvic RT Surgically Staged Patients Unanswered Questions Does surgical staging obviate the need for and benefit of pelvic RT in high risk patients? When is surgical staging adequate? Do the number of nodes matter? 5? 10? 15? Or more? Do where they are taken from matter?
75 A Phase III trial is needed comparing VB and pelvic RT in surgically staged patients Stage I-II patients TAH-BSO with bilateral pelvic and para-aortic lymphadenectomy Assessment of peritoneal cytology Regimen 1 Pelvic RT Regimen 2 Vaginal brachytherapy
76 Don t expect such a trial from the GOG An equivalency trial would require thousands of patients GOG 99 took 8 yrs to enroll <500 women PORTEC-2 trial is comparing VB and pelvic RT in early stage patients Unlike GOG, PORTEC-2 does not include surgical staging and will exclude truly high risk patients
77 So what to do with the individual patient?
78 Decision to irradiate (or not) rests on a careful assessment of the benefits and risks of treating (and of not treating) Likelihood of Cure/Toxicity With RT Likelihood of Salvage/Toxicity Without RT If delivered, select approach with the highest efficacy and lowest toxicity
79 Stage I Patients Limited*/No Lymph Node Surgery Grade 1 Grade 2 Grade 3 IA VB 2 IB -- 1 VB 2,3 VB 2,3 IC Pelvic 4,5 Pelvic 4,5 Pelvic 4,5 *<10 nodes, limited number of sites (arbitrary definition) 1 low risk of vaginal recurrence and nodal involvement 2 low risk of nodal involvement 3 Consider pelvic RT instead if +LVI and close to ½ MI 4 others favor Pelvic RT +VB particularly in g3, but pelvic RT alone associated with equivalent control and less toxicity 5 intensity modulated pelvic RT if possible
80 Pelvic RT and VB traditionally combined in pathologic stage I-II pts, notably stage IC Pelvic RT Pelvic+VB ICg1 24.9% 39.5% ICg2 29.9% 48.4% ICg3 27.4% 61.3% Small et al. Int J Radiat Oncol Biol Phys 2005;63:1502 But published data do not support the combined approach
81 256 stage I with deep MI on 7 studies Local Recurrence n Pelvic Pelvic+VB Eifel % Sause % Konski % Torissi % -- Piver 32 0% -- Rush 53 0% -- Weiss 61 0% -- Mean % 0.97% 1999;92:599
82 Complications also increased with combined approach Randall M et al. Intracavitary Cuff Boost after External Beam Irradiation In Early Endometrial Carcinoma Int J Radiat Oncol Biol Phys 1990;10:49 Rectal Bleeding/ Proctitis EBRT 3.8% EBRT+VB 18.6% p =.01 Lack of benefit and increased risk of toxicity strongly argue against the combined approach in high risk stage I disease
83 In surgically staged patients, VB alone is becoming the preferred adjuvant RT approach Stage I Patients Surgically Staged* Grade 1 Grade 2 Grade 3 IA VB 1 IB -- VB 1 VB 1 IC VB 2 VB 2 VB 2 *>10 nodes, multiple sites (arbitrary cutoff) 1 low risk of pelvic recurrence 2 consider pelvic RT if not extensive lymph node surgery
84 What about Stage II patients?
85 In stage II patients, base decisions on the extent of cervical involvement, myometrial invasion and surgical staging Stage II Patients Limited*/No Lymph Node Surgery Grade 1 Grade 2 Grade 3 IIA ½ MI VB 1 VB 1 VB 1 >½ MI Pelvic Pelvic Pelvic +/-VB +/-VB +/-VB IIB Pelvic+VB Pelvic+VB Pelvic+VB *<10 nodes, limited number of sites (arbitrary cutoff) 1 low risk of nodal involvement
86 VB may not be necessary in stage IIA pts undergoing pelvic RT Calvin DB, Connell PP, Rotmensch J, Mundt AJ Surgery and Postoperative RT in Stage II Endometrial Cancer AJCO 1999;22: pathologic Stage II patients 32 (73%) Stage IIA disease 18/32 stage IIA pts treated with pelvic RT alone None failed in the pelvis Median follow-up 40 months
87 As in stage I patients, one should favor VB alone in surgically staged stage II patients Stage II Patients Surgically Staged Patients* Grade 1 Grade 2 Grade 3 IIA ½ MI VB 1 VB 1 VB 1 >½ MI VB 2 VB 2 VB 2 IIB Pelvic+VB 3 Pelvic+VB 3 Pelvic+VB 3 *>15 nodes, multiple sites (arbitrary cutoff) 1 low risk of nodal involvement 2 favor pelvic RT if not extensive nodal surgery 3 only do VB alone reluctantly if extensive nodal surgery (note: pre-sacral lymph nodes are not routinely assessed!)
88 What about Chemotherapy? Imperial Beach
89 A strong rationale exists for chemotherapy in high risk early stage patients Creutzberg C et al. JCO 2004;22:1234
90 Previously, there was a push for replacing RT with chemotherapy GOG 156 Stage IB-IIB TAH-BSO Selective Pelvic & PA nodal dissection Regimen 1 Pelvic RT Regimen 2 Adriamycin Cisplatin However, it closed due to lack of accrual
91 The Europeans have completed such a trial 2006;95:266 Stage ICg3 Stage IIg3 >50% MI Stage III Regimen 1 Pelvic RT (45-50 Gy) Regimen 2 CDDP, Adriamycin, Cytoxan 5 cycles
92 2006;95:266 Median follow-up 95.5 months No difference in 5-year DFS or OS RT reduced local recurrence, chemotherapy reduced distant failure
93 Chemotherapy alone does not control local disease Pelvic failure-free survival with (1) and without (0) cervical involvement 43 high-risk patients Adjuvant chemotherapy alone 17 (40%) failed in the pelvis 3-year actuarial pelvic failure 46.5% Factors predictive of pelvic relapse: +cervix, stage I-II disease Int J Radiat Oncol Biol Phys 2001;50:1145
94 Chemotherapy Such results suggest that a more prudent approach would be to combine chemotherapy and RT Published trials, however, have reported mixed results
95 GOG 34 Morrow (1990) Clinical Stage I-II TAH BSO Surgical Staging 1 or more risk factors >1/2 MI Pelvic/PA nodes Cervical involvement Adnexal involvement Pelvic +/- Paraortic Irradiation No Vaginal Brachy Regimen 1 Doxorubicin 60 mg/m 2 N= 92 Regimen 2 No further therapy N=89 Morrow et al. Gynecol Oncol 1990;36:166
96 GOG 34 Chemotherapy did not improve outcome 3-yr Extra-Pelvic Survival Failure RT alone 75% 22.5% RT +Adriamycin 68% 16.3% p = NS p = NS Moreover, 12 (7%) of these surgically staged patients developed a SBO after pelvic +/- PART But maybe adriamycin alone is not enough
97 To test a more aggressive regimen, the RTOG launched RTOG ;103:155 Stage I-III TAH-BSO +/- Nodal Surgery Grade 2-3 >1/2 MI +Cervical Stroma Extra-uterine (pelvic only) disease +washings Pelvic RT 45 Gy +VB CDDP 50 mg/m 2 Days 1,28 Maintenance Chemo CDDP 50 mg/m 2 + Paclitaxel 175 mg/m 2
98 RTOG 9708 Unsurprisingly, acute toxicities were significant (predominantly hematologic) 29% grade 3-4 (concomitant phase) 83% grade 3-4 (chemotherapy phase) High rate of chronic toxicity also seen 41% grade 2, 16% grade 3, 5% grade 4
99 Loco-regional control was high (>95%), Extra-pelvic recurrences were common (4-yr distant metastases 19%) 2-yr DFS 83% Based on these results, a randomized trial was initiated (RTOG 9905) Unfortunately, closed due to poor accrual
100 Combined Modality Trials Several new combined modality trials are underway or in the planning stages PORTEC-3 comparing pelvic RT versus pelvic RT + chemotherapy in high risk pts New GOG trial (concept only) compares pelvic RT versus VB + chemotherapy in surgically staged patients
101 Conclusions RT continues to play an important role in early stage endometrial cancer Its optimal role is still evolving Attention turning to combined modality approaches in high risk patients following surgery Novel approaches, notably IMRT, should help improve the quality and delivery of RT in these women
Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
More informationSentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
More informationEndometrial Cancer. William Small Jr., MD Professor of Radiation Oncology The Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Endometrial Cancer William Small Jr., MD Professor of Radiation Oncology The Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives: Discuss the role of radiation therapy
More informationHow To Treat A Uterine Sarcoma
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas
More informationPRIMARY TREATMENT CLINICAL PRESENTATION INITIAL EVALUATION. Conclude procedure with/without lymph node dissection
INITIAL EVALUATION History and Physical CXR Pathology review 1 Labs Consider CA125, and pre-operative imaging of abdomen and pelvis Screen for Lynch Syndrome by family history or molecular testing CLINICAL
More informationHow To Compare The Effects Of A Hysterectomy And A Hysterectomy
A RANDOMIZED TRIAL COMPARING RADICAL HYSTERECTOMY AND PELVIC NODE DISSECTION VS SIMPLE HYSTERECTOMY AND PELVIC NODE DISSECTION IN PATIENTS WITH LOW RISK EARLY STAGE CERVICAL CANCER A Gynecologic Cancer
More informationTreatment Volume and Technique
RADIATION THERAPY The standard of care for early lesions is surgical resection; however, selected patients with small central lesions may be considered for definitive radiation, particularly when the lesions
More informationRe irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure
Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent Cervical lcancer Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan
More informationBrachytherapy of the Uterine Corpus: Some Physical Considerations. Bruce Thomadsen. University of Wisconsin -Madison
Brachytherapy of the Uterine Corpus: Some Physical Considerations Bruce Thomadsen University of Wisconsin -Madison Conflicts of Interest The author has no known conflicts involving this presentation Learning
More informationStomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
More informationSpecial Article. Received 2 December 2013; accepted 15 January 2014. Practical Radiation Oncology (2014) 4, 137 144. www.practicalradonc.
Practical Radiation Oncology (2014) 4, 137 144 www.practicalradonc.org Special Article The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation
More informationSurgical Staging of Endometrial Cancer
Surgical Staging of Endometrial Cancer I. Endometrial Cancer Surgical Staging Overview Uterine cancer types: carcinomas type I and type II, sarcomas, carcinosarcomas Hysterectomy with BSO Surgical Staging
More informationEndometrial Cancer. Ellen Jones MD PhD University of North Carolina
The Management of Endometrial Cancer Ellen Jones MD PhD University of North Carolina Disclosure I have no conflicts of interest to disclose. Learning Objectives Describe the epidemiology, clinical presentation,
More informationRole of IMRT in the Treatment of Gynecologic Malignancies. John C. Roeske, PhD Associate Professor The University of Chicago
Role of IMRT in the Treatment of Gynecologic Malignancies John C. Roeske, PhD Associate Professor The University of Chicago Acknowledgements B Aydogan, PhD Univ of Chicago P Chan, MD Princess Margaret
More informationOutcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy
ORIGINAL ARTICLES 613 Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy S K Tay,*FAMS, MD, FRCOG, L K Tan,**MBBS, M Med (O & G), MRCOG Abstract
More informationEndometrial Cancer. GYNE/ONC Practice Guideline. Approval Date: February 2011 V2.3 converted file format
Endometrial Cancer GYNE/ONC Practice Guideline Approval Date: February 2011 V2.3 converted file format This guideline is a statement of consensus of the Gynecologic Oncology Disease Site Team regarding
More informationUnderstanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE
Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE Introduction This guide is designed to help you clarify and understand the decisions that need to be made about your care for the
More informationInvasive Cervical Cancer. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Invasive Cervical Cancer Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Etiology Human Papilloma Virus (HPV): Detected in 99.7% of cervical cancers Cancer
More informationRadiation Therapy for Prostate Cancer: Treatment options and future directions
Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment
More informationProtons vs. CyberKnife. Protons vs. CyberKnife. Page 1 UC SF. What are. Alexander R. Gottschalk, M.D., Ph.D.
Protons vs. CyberKnife UC SF Protons vs. CyberKnife UC SF Alexander R. Gottschalk, M.D., Ph.D. Associate Professor and Director of the CyberKnife Radiosurgery Program Department of Radiation Oncology University
More informationEndometrial Cancer Treatment
Endometrial Cancer Treatment January 2006 By Shelly Smits, RHIT, CCS, CTR mary by Ian Thompson, MD Data Source: Cancer registry information on uterine cancer diagnosed 1/1/2000 to 12/31/2004. Reason for
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationThe Role of Laparoscopy in Endometrial Cancer
The Role of Laparoscopy in Endometrial Cancer Prof. Dr. Tugan BEŞE İstanbul University, Cerrahpaşa Medical Faculty Gynecologic Oncology Department Surgical staging in Endometrial Cancer Laparoscopic surgery
More informationOverview of Gynaecologic Cancer
Overview of Gynaecologic Cancer Stuart Salfinger Gynaecologic Oncologist St John of God Hospital King Edward Memorial Hospital Cervical Cancer Cervical Cancer Risk HPV Smoking?OCP Cervical Cancer Symptoms
More informationEndometrial cancer-carcinoma of the lining of the uterus-is the most common gynecologic
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4th Edition 2001 Uterus: Endometrial Carcinoma Jeffrey L. Stern, MD Endometrial
More informationMonthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix
Original Article Free full text available from www.cancerjournal.net Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix Mishra Sanjib K, Laskar Siddhartha, Muckaden Mary Ann,
More informationOriginal Date: June 2013 CERVICAL CANCER
National Imaging Associates, Inc. Clinical guideline Original Date: June 2013 CERVICAL CANCER Page 1 of 6 Radiation Oncology Last Review Date: September 2015 Guideline Number: NIA_CG_223 Last Revised Date:
More informationCervical Cancer: Definitive Chemoradiation
Cervical Cancer: Definitive Chemoradiation Huma Chaudhry Jordan Kharofa Faculty: Dr. Beth Erickson, MD Medical College of Wisconsin Department of Radiation Oncology July 14, 2013 Clinical Presentation
More informationGYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision
RADIATION THERAPY FOR GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY FACTS ABOUT GYNECOLOGIC CANCERS Gynecologic cancers
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of radical laparoscopic hysterectomy for early stage cervical cancer Introduction This overview
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationCHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
More informationConcurrent Chemotherapy and Radiotherapy for Head and Neck Cancer
Concurrent Chemotherapy and Radiotherapy for Head and Neck Cancer Ryan J. Burri; Nancy Y. Lee Published: 03/23/2009 Abstract and Introduction Abstract Head and neck cancer is best managed in a multidisciplinary
More informationRadioterapia panencefalica. Umberto Ricardi
Radioterapia panencefalica Umberto Ricardi Background Systemic disease to the brain is unfortunately a quite common event Radiotherapy, especially with the great technical development during the past decades,
More informationSCAN Gynaecological Group. Clinical Management Protocols: Cancer of the Cervix. www.scan.scot.nhs.uk
SE Scotland Cancer Network SCAN Gynaecological Group Clinical Management Protocols: Cancer of the Cervix www.scan.scot.nhs.uk Table of contents 3 Introduction 4 Diagnosis 5-6 Staging and spread of disease
More informationCarcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is
More informationNursing Care of the Patient Receiving Brachytherapy for Gynecologic Cancer
Nursing Care of the Patient Receiving Brachytherapy for Gynecologic Cancer Una Randall, RN, BSN, OCN Dana Farber / Brigham and Women s Cancer Center Department of Radiation Oncology Una Randall is not
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationApproccio multidisciplinare nei tumori del retto
Approccio multidisciplinare nei tumori del retto F. Muñoz Radiation Oncology Department University of Torino, Italy RECENT CHANGES IN RECTAL CANCER DIAGNOSIS AND THERAPY Optimal staging by EUS and MRI
More informationAn Intergroup trial of the Dutch Cooperative Gynecologic Oncology Group and the UK National Cancer Research Institute
Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3 An Intergroup trial
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More information10 TREATMENT OF ENDOMETRIAL CANCER
10 TREATMENT OF ENDOMETRIAL CANCER Lois M. Ramondetta, Thomas W. Burke, Russell Broaddus, and Anuja Jhingran Chapter Outline Chapter Overview.......................................... 148 Introduction...............................................
More informationWhat is neuroendocrine cervical cancer?
Key Points: 1. Neuroendocrine cancer of the uterine cervix is a rare and aggressive disease. 2. Treatment for neuroendocrine cervical cancer is usually more intensive than that for most other types of
More informationCurrent Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
More informationRectal Cancer. To Radiate or not to radiate? Q: Should rectal cancer RT/CRT decisions be based solely on stage? 11/09/2014
Rectal Cancer To Radiate or not to radiate?? Dr. Corinne Doll Radiation Oncologist Tom Baker Cancer Centre Calgary, Alberta Q: Should rectal cancer RT/CRT decisions be based solely on stage? 1 Q: Can RT/CRT
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationChapter 14 Cancer of the Cervix Uteri
Carol L. Kosary Introduction Despite the existence of effective screening through the use of Pap smears since the 195 s, there were 9,71 estimated cases of invasive cervical cancer and 3,7 deaths in 26
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationClinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto
Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationintensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis 11/2009 5/2016 5/2017 5/2016
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Abdomen File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis
More informationManagement of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
More informationEndometrial Cancer. Measurability of Quality Performance Indicators Version 2.0
Endometrial Cancer Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Endometrial Cancer QPIs Final Publication v2 Endometrial QPI Dataset (latest published version)
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationThe Role of Adjuvant Therapy in Endometrial Cancer
No. 290, April 2013 The Role of Adjuvant Therapy in Endometrial Cancer This clinical practice guideline has been prepared by the SOGC-GOC-SCC Policy and Practice Guidelines Committee and approved by the
More informationLaparoscopic hysterectomy with or without pelvic. lymphadenectomy or sampling in a high-risk series of
Laparoscopic hysterectomy with or without pelvic lymphadenectomy or sampling in a high-risk series of patients with endometrial cancer Susan F Willis Thomas EJ Ind * Desmond Barton Department of Gynaecological
More informationthe standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009
Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
More informationThe role of vaginal hysterectomy in the treatment of endometrial carcinoma
Int J Gynecol Cancer 1994, 4, 342-347 The role of vaginal hysterectomy in the treatment of endometrial carcinoma R. J. LELLI~*, G. W. MORLEY* & W. A. PETERS ~ *Department of Obstetrics and Gynecology,
More informationNeoadjuvant therapy are we doing it right? Short course and chemoradiation
Neoadjuvant therapy are we doing it right? Short course and chemoradiation Rob Glynne-Jones Mount Vernon Cancer Centre Relevant Endpoints in rectal cancer Local recurrence Disease-free survival Overall
More informationRadiation Therapy in Prostate Cancer Current Status and New Advances
Radiation Therapy in Prostate Cancer Current Status and New Advances Arno J. Mundt MD Professor and Chairman Dept Radiation Oncology Moores Cancer Center UCSD Presentation Welcome Overview of UCSD, Moores
More informationGynecologic Oncology
Gynecologic Oncology 115 (2009) 142 153 Contents lists available at ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno Review Management of women with uterine papillary
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationPrinciples of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
More informationRadiation Therapy in Prostate Cancer Current Status and New Advances
Radiation Therapy in Prostate Cancer Current Status and New Advances Arno J. Mundt MD Professor and Chairman Dept Radiation Oncology Moores Cancer Center UCSD Radiation Therapy Wilhelm Roentgen (1845-1923)
More informationThe evolution of rectal cancer therapy. Objectives
The evolution of rectal cancer therapy Hagen Kennecke MD MHA FRCPC Western Canada Consensus Conference September 5, 2014 Objectives Identify standard therapy: stage II/III rectal cancer Update recent adjuvant
More informationTITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.
SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationCANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015. 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV
CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV Meta-analisis LACE: adyuvancia vs no adyuvancia Pignon JP, et al.
More informationRole of Robotic Surgery in Obese Women with Endometrial Cancer
Role of Robotic Surgery in Obese Women with Endometrial Cancer Anil Tailor Consultant Gynaecological Oncologist Royal Surrey County Hospital Guildford, Surrey, UK St Peters Hospital Chertsey, Surrey, UK
More informationTransition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience. Richard Pötter MD. BrachyNext, Miami, 2014.
Transition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience Richard Pötter MD BrachyNext, Miami, 2014 Disclosures Richard Pötter, MD, does not have any financial relationships or
More informationAdjuvant chemotherapy for endometrial cancer after hysterectomy (Review)
Adjuvant chemotherapy for endometrial cancer after hysterectomy (Review) Johnson N, Bryant A, Miles T, Hogberg T, Cornes P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane
More informationProvincial Cervical Cancer Treatment Guidelines
Provincial Cervical Cancer Treatment Guidelines Approved at the Provincial Gyne-Oncology Guideline Meeting January 11, 2013 Clinical practice guidelines have been developed after multi-disciplinary consensus
More informationDate: 06/06/2014 Our ref: 4496. I write in response to your request for information in relation to treatment for endometrial cancer in NHS Lothian.
Lothian NHS Board Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG Telephone 0131 536 9000 Fax 0131 536 9088 www.nhslothian.scot.nhs.uk Date: 06/06/2014 Our ref: 4496 Enquiries to: Bryony Pillath Extension:
More informationOncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
More informationCorporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate
Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate
More informationPreoperative Radiotherapy for Inoperable Stage II Endometrial Cancer: Insights into Improving Treatment and Outcomes
Preoperative Radiotherapy for Inoperable Stage II Endometrial Cancer: Insights into Improving Treatment and Outcomes Marette H. Lee, MD, Christina Aquino-Parsons, MD, Paul J. Hoskins, MD, Peter Lim, MD,
More informationRole of Radiation after Radical Prostatectomy Review of Literature
Vol. 9, No: 1 Jan - Jun 2013. Page 1-44 Role of Radiation after Radical Prostatectomy Review of Literature S.K. Raghunath, N. Srivatsa Abstract Biochemical relapse after radical prostatectomy occurs in
More informationEvolution of radical hysterectomy for cervical cancer along the last two decades: single institution experience
Original Article Evolution of radical hysterectomy for cervical cancer along the last two decades: single institution experience Claudia Arispe, Ana Isabel Pomares, Javier De Santiago, Ignacio Zapardiel
More informationTreatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationOutcomes of High-Dose-Rate Interstitial Brachytherapy in the Treatment of Locally Advanced Cervical Cancer: Long-term Results
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Gynecologic Cancer Outcomes of High-Dose-Rate Interstitial Brachytherapy in the Treatment of Locally
More informationTotal laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival
Gynecologic Oncology 92 (2004) 789 793 www.elsevier.com/locate/ygyno Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival Andreas Obermair, a,b, * Tom P. Manolitsas,
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationPRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology
PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI
More informationTry out the online ROMA calculator available on the Elecsys HE4 page at cobas.com
Try out the online calculator available on the Elecsys HE4 page at cobas.com Download the Roche application for the iphone and the ipad from the App Store. Roche References 1 Huhtinen, K. et al. (29).
More informationNCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms V.1.2007. Continue. www.nccn.org
Clinical in Oncology Uterine Neoplasms V.1.2007 Continue www.nccn.g Panel Members * Benjamin E. Greer, MD/Chair Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance * Wui-Jin Koh, MD/Associate
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationProton Therapy for Prostate Cancer
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Director, Proton Therapy Center Associate Professor Department of Radiation Oncology M.D. Anderson Cancer Center Randomized studies showing benefit
More informationPatient Guide. The precise answer for tackling cervical cancer. Brachytherapy: Because life is for living
Patient Guide Brachytherapy: The precise answer for tackling cervical cancer Because life is for living The aim of this booklet is to help women who have been diagnosed with cervical cancer and their family
More informationAccelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationGoals and Objectives: Breast Cancer Service Department of Radiation Oncology
Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including
More informationRole of external irradiation in high-risk resected colon cancer
Original Article Role of external irradiation in high-risk resected colon cancer Ahmadloo Niloofar, Mosalaei Ahmad, Omidvari Shapour, Mohammadianpanah Mohammad Department of Radiation Oncology, Nemazee
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationMetastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Sarah Hutto,, MSIV Marc Underhill, M.D. January 27, 2009 Past History 45 yo female
More information